Table 1.

Clinical Trials Included in Analyses

	EVOLVE‐1	EVOLVE‐2	REGAIN
NCT number	NCT02614183	NCT02614196	NCT02614261
Number of patients randomized and treated (ITT)	858	915	1113
Study centers	90 in United States and Canada	109 in Asia, Europe, North, and South America	116 in Asia, Europe, North, and South America
Headache frequency	4‐14 migraine headache days/month (episodic migraine)	4‐14 migraine headache days/month (episodic migraine)	≥15 headache days/month† (chronic migraine)
Baseline period	30‐40 days	30‐40 days	30‐40 days
Double‐blind period	6 months	6 months	3 months
Follow‐up period	4 months	4 months	4 months
Additional migraine preventive medications	Not permitted	Not permitted	Stable doses of allowed treatments permitted‡
Trial phase	3	3	3
PBO‐controlled	Yes	Yes	Yes
Treatment groups	GMB 120 mg with 240 mg loading dose	GMB 120 mg with 240 mg loading dose	GMB 120 mg with 240 mg loading dose
	GMB 240 mg	GMB 240 mg	GMB 240 mg
	PBO	PBO	PBO
Treatment regimen	Monthly subcutaneous injection	Monthly subcutaneous injection	Monthly subcutaneous injection

^†At least 8 of the monthly headache days were migraine headache days.

^‡Permitted migraine preventive medications included topiramate and propranolol.

GMB = galcanezumab; ITT = intent‐to‐treat population; NCT = national clinical trial; PBO = placebo.